Drug pricing transparency
Drug pricing transparency requirements are creating direct friction points for Trade and Geopolitical Risk teams, particularly as the U.S. Centers for Medicare and Medicaid Services and the U.S. Food and Drug Administration push disclosure mandates that touch cross-border supply chain structures and foreign reference pricing arrangements. The Office of the United States Trade Representative has flagged several trading partner pricing regimes as potential non-tariff barriers, meaning what looks like a domestic compliance obligation can carry bilateral trade agreement implications. Compliance teams are currently mapping distributor and licensing agreements against CMS's Drug Price Transparency rule to determine whether foreign counterparty arrangements trigger reportable benchmarks.
Watch
- CMS Drug Price Transparency rule: which cross-border arrangements trigger disclosure
- USTR watch-list designations for foreign reference pricing as non-tariff barriers
- Proposed EU Pharmaceutical Strategy provisions affecting U.S. drug import pricing terms
- Congressional proposals to tie Most Favored Nation pricing to trade agreement enforcement mechanisms
Recent material activity in Trade & Geopolitical Risk
-
OFAC designates 14 entities linked to Russian defense procurement network
The Treasury Department's Office of Foreign Assets Control added 14 entities and 6 individuals to the Specially Designated Nationals list for their roles in procuring critical technology components for Russia's defense i…
Read a full sample brief → -
BIS adds 22 Chinese semiconductor entities to Entity List for advanced chip diversion
The Bureau of Industry and Security expanded export controls targeting Chinese semiconductor entities found to be diverting advanced computing chips through third-country intermediaries. New license requirements affect i…
Read a full sample brief →